Home › Funds › Frazier Life Sciences Management, L.P. › ASND
Frazier Life Sciences Management, L.P. position in ASND
ASCENDIS PHARMA A/S · Health Care
Frazier Life Sciences Management, L.P. reported holding 225,155 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$60.1M, representing 1.31% of its reported portfolio and ranking #15 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed ASND holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s ASND position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in ASND in Q3 2024 at 133,333 shares (US$19.9M). The position peaked in Q2 2026 at 225,155 shares, worth US$60.1M. Across 8 filings, Frazier Life Sciences Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 225,155 shares valued at US$60.1M — an increase of 91,822 shares quarter over quarter.. Notable position changes include a 69% increase in Q2 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 133.33K | $19.91M | New |
| Q4 2024 | 133.33K | $18.36M | Hold |
| Q1 2025 | 133.33K | $20.78M | Hold |
| Q2 2025 | 133.33K | $23.01M | Hold |
| Q3 2025 | 133.33K | $26.51M | Hold |
| Q4 2025 | 133.33K | $28.43M | Hold |
| Q1 2026 | 133.33K | $30.50M | Hold |
| Q2 2026 | 225.16K | $60.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Spyglass Capital Management LLC 215.40K sh · $57.45M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held ASND?
Frazier Life Sciences Management, L.P. has disclosed ASND holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is Frazier Life Sciences Management, L.P.'s current position in ASND?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 225.16K shares of ASND (ASCENDIS PHARMA A/S), valued at $60.05M, representing 1.31% of its reported portfolio and ranking #15.
Has Frazier Life Sciences Management, L.P. been buying or selling ASND?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. increased its position in ASND. The position peaked in Q2 2026 at 225.16K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.